Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial

Ganesh Raghu, Rachel Million-Rousseau, Adele Morganti, Loïc Perchenet, Juergen Behr, N. Goh, A. Glanville, M. Musk, P. Hopkins, D. C. Lien, C. Chan, J. D. Rolf, P. Wilcox, P. G. Cox, H. Manganas, V. Cottin, D. Valeyre, B. Walleart, S. Andreas, C. NeurohrA. Guenther, N. Schönfeld, A. Koch, M. Kramer, R. Breuer, I. Ben-Dov, G. Fink, Y. Schwarz, C. Albera, M. Confalonieri, C. Saltini, S. Harari, M. Flezar, M. Greenblatt, G. J. Ras, F. Morell, J. L. Alvarez-Sala, A. Xaubet, A. Sueiro, M. J. Linares, M. Sköld, O. Kayacan, N. Mogulkoc, Andrew Chan, J. Chapman, J. Parambil, N. Ettinger, J. Golden, K. C. Meyer, J. J. Swigris, G. L. Yung, D. Antin-Ozerkis, P. K. Mohabir, L. J. Wesselius, J. De Andrade, F. Cordova, Z. Safdar, M. Wencel

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of

Original languageEnglish (US)
Pages (from-to)1622-1632
Number of pages11
JournalEuropean Respiratory Journal
Volume42
Issue number6
DOIs
StatePublished - Dec 1 2013

Fingerprint

Idiopathic Pulmonary Fibrosis
Randomized Controlled Trials
Therapeutics
Placebos
Safety
macitentan

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., Goh, N., ... Wencel, M. (2013). Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial. European Respiratory Journal, 42(6), 1622-1632. https://doi.org/10.1183/09031936.00104612

Macitentan for the treatment of idiopathic pulmonary fibrosis : The randomised controlled MUSIC trial. / Raghu, Ganesh; Million-Rousseau, Rachel; Morganti, Adele; Perchenet, Loïc; Behr, Juergen; Goh, N.; Glanville, A.; Musk, M.; Hopkins, P.; Lien, D. C.; Chan, C.; Rolf, J. D.; Wilcox, P.; Cox, P. G.; Manganas, H.; Cottin, V.; Valeyre, D.; Walleart, B.; Andreas, S.; Neurohr, C.; Guenther, A.; Schönfeld, N.; Koch, A.; Kramer, M.; Breuer, R.; Ben-Dov, I.; Fink, G.; Schwarz, Y.; Albera, C.; Confalonieri, M.; Saltini, C.; Harari, S.; Flezar, M.; Greenblatt, M.; Ras, G. J.; Morell, F.; Alvarez-Sala, J. L.; Xaubet, A.; Sueiro, A.; Linares, M. J.; Sköld, M.; Kayacan, O.; Mogulkoc, N.; Chan, Andrew; Chapman, J.; Parambil, J.; Ettinger, N.; Golden, J.; Meyer, K. C.; Swigris, J. J.; Yung, G. L.; Antin-Ozerkis, D.; Mohabir, P. K.; Wesselius, L. J.; De Andrade, J.; Cordova, F.; Safdar, Z.; Wencel, M.

In: European Respiratory Journal, Vol. 42, No. 6, 01.12.2013, p. 1622-1632.

Research output: Contribution to journalArticle

Raghu, G, Million-Rousseau, R, Morganti, A, Perchenet, L, Behr, J, Goh, N, Glanville, A, Musk, M, Hopkins, P, Lien, DC, Chan, C, Rolf, JD, Wilcox, P, Cox, PG, Manganas, H, Cottin, V, Valeyre, D, Walleart, B, Andreas, S, Neurohr, C, Guenther, A, Schönfeld, N, Koch, A, Kramer, M, Breuer, R, Ben-Dov, I, Fink, G, Schwarz, Y, Albera, C, Confalonieri, M, Saltini, C, Harari, S, Flezar, M, Greenblatt, M, Ras, GJ, Morell, F, Alvarez-Sala, JL, Xaubet, A, Sueiro, A, Linares, MJ, Sköld, M, Kayacan, O, Mogulkoc, N, Chan, A, Chapman, J, Parambil, J, Ettinger, N, Golden, J, Meyer, KC, Swigris, JJ, Yung, GL, Antin-Ozerkis, D, Mohabir, PK, Wesselius, LJ, De Andrade, J, Cordova, F, Safdar, Z & Wencel, M 2013, 'Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial', European Respiratory Journal, vol. 42, no. 6, pp. 1622-1632. https://doi.org/10.1183/09031936.00104612
Raghu, Ganesh ; Million-Rousseau, Rachel ; Morganti, Adele ; Perchenet, Loïc ; Behr, Juergen ; Goh, N. ; Glanville, A. ; Musk, M. ; Hopkins, P. ; Lien, D. C. ; Chan, C. ; Rolf, J. D. ; Wilcox, P. ; Cox, P. G. ; Manganas, H. ; Cottin, V. ; Valeyre, D. ; Walleart, B. ; Andreas, S. ; Neurohr, C. ; Guenther, A. ; Schönfeld, N. ; Koch, A. ; Kramer, M. ; Breuer, R. ; Ben-Dov, I. ; Fink, G. ; Schwarz, Y. ; Albera, C. ; Confalonieri, M. ; Saltini, C. ; Harari, S. ; Flezar, M. ; Greenblatt, M. ; Ras, G. J. ; Morell, F. ; Alvarez-Sala, J. L. ; Xaubet, A. ; Sueiro, A. ; Linares, M. J. ; Sköld, M. ; Kayacan, O. ; Mogulkoc, N. ; Chan, Andrew ; Chapman, J. ; Parambil, J. ; Ettinger, N. ; Golden, J. ; Meyer, K. C. ; Swigris, J. J. ; Yung, G. L. ; Antin-Ozerkis, D. ; Mohabir, P. K. ; Wesselius, L. J. ; De Andrade, J. ; Cordova, F. ; Safdar, Z. ; Wencel, M. / Macitentan for the treatment of idiopathic pulmonary fibrosis : The randomised controlled MUSIC trial. In: European Respiratory Journal. 2013 ; Vol. 42, No. 6. pp. 1622-1632.
@article{39fb34eb6d0b4a0487c8ae7e61f6154e,
title = "Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial",
abstract = "Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of",
author = "Ganesh Raghu and Rachel Million-Rousseau and Adele Morganti and Lo{\"i}c Perchenet and Juergen Behr and N. Goh and A. Glanville and M. Musk and P. Hopkins and Lien, {D. C.} and C. Chan and Rolf, {J. D.} and P. Wilcox and Cox, {P. G.} and H. Manganas and V. Cottin and D. Valeyre and B. Walleart and S. Andreas and C. Neurohr and A. Guenther and N. Sch{\"o}nfeld and A. Koch and M. Kramer and R. Breuer and I. Ben-Dov and G. Fink and Y. Schwarz and C. Albera and M. Confalonieri and C. Saltini and S. Harari and M. Flezar and M. Greenblatt and Ras, {G. J.} and F. Morell and Alvarez-Sala, {J. L.} and A. Xaubet and A. Sueiro and Linares, {M. J.} and M. Sk{\"o}ld and O. Kayacan and N. Mogulkoc and Andrew Chan and J. Chapman and J. Parambil and N. Ettinger and J. Golden and Meyer, {K. C.} and Swigris, {J. J.} and Yung, {G. L.} and D. Antin-Ozerkis and Mohabir, {P. K.} and Wesselius, {L. J.} and {De Andrade}, J. and F. Cordova and Z. Safdar and M. Wencel",
year = "2013",
month = "12",
day = "1",
doi = "10.1183/09031936.00104612",
language = "English (US)",
volume = "42",
pages = "1622--1632",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - Macitentan for the treatment of idiopathic pulmonary fibrosis

T2 - The randomised controlled MUSIC trial

AU - Raghu, Ganesh

AU - Million-Rousseau, Rachel

AU - Morganti, Adele

AU - Perchenet, Loïc

AU - Behr, Juergen

AU - Goh, N.

AU - Glanville, A.

AU - Musk, M.

AU - Hopkins, P.

AU - Lien, D. C.

AU - Chan, C.

AU - Rolf, J. D.

AU - Wilcox, P.

AU - Cox, P. G.

AU - Manganas, H.

AU - Cottin, V.

AU - Valeyre, D.

AU - Walleart, B.

AU - Andreas, S.

AU - Neurohr, C.

AU - Guenther, A.

AU - Schönfeld, N.

AU - Koch, A.

AU - Kramer, M.

AU - Breuer, R.

AU - Ben-Dov, I.

AU - Fink, G.

AU - Schwarz, Y.

AU - Albera, C.

AU - Confalonieri, M.

AU - Saltini, C.

AU - Harari, S.

AU - Flezar, M.

AU - Greenblatt, M.

AU - Ras, G. J.

AU - Morell, F.

AU - Alvarez-Sala, J. L.

AU - Xaubet, A.

AU - Sueiro, A.

AU - Linares, M. J.

AU - Sköld, M.

AU - Kayacan, O.

AU - Mogulkoc, N.

AU - Chan, Andrew

AU - Chapman, J.

AU - Parambil, J.

AU - Ettinger, N.

AU - Golden, J.

AU - Meyer, K. C.

AU - Swigris, J. J.

AU - Yung, G. L.

AU - Antin-Ozerkis, D.

AU - Mohabir, P. K.

AU - Wesselius, L. J.

AU - De Andrade, J.

AU - Cordova, F.

AU - Safdar, Z.

AU - Wencel, M.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of

AB - Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of

UR - http://www.scopus.com/inward/record.url?scp=84888166435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888166435&partnerID=8YFLogxK

U2 - 10.1183/09031936.00104612

DO - 10.1183/09031936.00104612

M3 - Article

C2 - 23682110

AN - SCOPUS:84888166435

VL - 42

SP - 1622

EP - 1632

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 6

ER -